Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Items 101–200 of 1,001
Duffy, C., Sorolla, A., Wang, E., Golden, E., Woodward, E., Davern, K., Ho, D., Johnstone, E., Pfleger, K., Redfern, A., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00129-0 · Cited by 179
Luque-Cabal, M., García-Teijido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s34537 · Cited by 179
Wang, H., & Yee, D. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00334-2 · Cited by 173
A framework for understanding and targeting residual disease in oncogene-driven solid cancers
Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 181
Real-World Evidence in Oncology: Opportunities and Limitations
Di Maio, M., Perrone, F., & Conte, P. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0647 · Cited by 168
Murthy, R., Borges, V. F., Conlin, A., Chaves, J., Chamberlain, M., Gray, T., Vo, A., & Hamilton, E. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30256-0 · Cited by 170
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Hafeez, U., Gan, H. K., & Scott, A. M. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.05.010 · Cited by 176
Miller, K., Cortes, J., Hurvitz, S. A., Krop, I. E., Tripathy, D., Verma, S., Riahi, K., Reynolds, J. G., Wickham, T. J., Molnar, I., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2385-z · Cited by 168
Self-citationNarayan, P., Osgood, C. L., Singh, H., Chiu, H.-J., Ricks, T. K., Chiu Yuen Chow, E., Qiu, J., Song, P., Yu, J., Namuswe, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4557 · Cited by 167
Prat, A., Pascual, T., De Angelis, C., Gutierrez, C., Llombart-Cussac, A., Wang, T., Cortés, J., Rexer, B., Paré, L., Forero, A., et al. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz042 · Cited by 175
Self-citationHER2+ breast cancer treatment and cardiotoxicity: monitoring and management
Jerusalem, G., Lancellotti, P., & Kim, S.-B. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05303-y · Cited by 168
Self-citationWhat Is Known about Breast Cancer in Young Women?
Zhu, J. W., Charkhchi, P., Adekunte, S., & Akbari, M. R. (2023) · Cancers · doi:10.3390/cancers15061917 · Cited by 226
Breast cancer brain metastases: the last frontier
Leone, J. P., & Leone, B. A. (2015) · Experimental Hematology & Oncology · doi:10.1186/s40164-015-0028-8 · Cited by 168
Activating HER2 mutations as emerging targets in multiple solid cancers
Connell, C. M., & Doherty, G. J. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000279 · Cited by 166
An Introduction to Survival Statistics: Kaplan-Meier Analysis
N. Dudley, P., Wickham, P., & Coombs, M. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.1.8 · Cited by 168
“Estimates of OS shown in Table 3 illustrate the fact that the likelihood of being alive was greater at 1, 2, 3, and 4 years for patients receiving pertuzumab than those in the control group (Swain et al., 2015).”
BackgroundMethodInfluentialNitz, U. A., Gluz, O., Christgen, M., Grischke, E. M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx494 · Cited by 167
André, F., Hurvitz, S., Fasolo, A., Tseng, L.-M., Jerusalem, G., Wilks, S., O’Regan, R., Isaacs, C., Toi, M., Burris, H. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9161 · Cited by 166
Johnston, S. R. D., Hegg, R., Im, S.-A., Park, I. H., Burdaeva, O., Kurteva, G., Press, M. F., Tjulandin, S., Iwata, H., Simon, S. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7824 · Cited by 165
RetractedRadical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial
Trovo, M., Furlan, C., Polesel, J., Fiorica, F., Arcangeli, S., Giaj-Levra, N., Alongi, F., Del Conte, A., Militello, L., Muraro, E., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.08.032 · Cited by 165
Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment
Gu, G., Dustin, D., & Fuqua, S. A. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.11.005 · Cited by 163
Reactive Oxygen Species‐Mediated Mechanisms of Action of Targeted Cancer Therapy
Teppo, H.-R., Soini, Y., & Karihtala, P. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1485283 · Cited by 162
Mechanisms of lapatinib resistance in HER2-driven breast cancer
D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., & Bianco, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.08.001 · Cited by 164
Costa, R. L. B., & Czerniecki, B. J. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0153-3 · Cited by 158
Physical biology of the cancer cell glycocalyx
Kuo, J. C.-H., Gandhi, J. G., Zia, R. N., & Paszek, M. J. (2018) · Nature Physics · doi:10.1038/s41567-018-0186-9 · Cited by 161
Mechanisms and Therapy for Cancer Metastasis to the Brain
Franchino, F., Rudà, R., & Soffietti, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00161 · Cited by 179
Lynce, F. C., Barac, A., Geng, X., Dang, C. T., Yu, A. F., Smith, K. L., Gallagher, C., Pohlmann, P., Nunes, R., Herbolsheimer, P. M., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05191-2 · Cited by 154
Self-citationHarbeck, N., Gluz, O., Christgen, M., Kates, R. E., Braun, M., Küemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9815 · Cited by 153
Jain, S., Shah, A. N., Santa-Maria, C. A., Siziopikou, K. P., RADEMAKER, A. W., Helenowski, I., Cristofanilli, M., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4792-0 · Cited by 152
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 173
Shah, N., Mohammad, A. S., Saralkar, P. A., Sprowls, S. A., Vickers, S. D., John, D. Q., Tallman, R. M., Lucke-Wold, B. P., Jarrell, K. L., Pinti, M. V., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.021 · Cited by 157
Wang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 193
Hyman, D. M., Solit, D. B., Arcila, M. E., Cheng, D. T., Sabbatini, P., Baselga, J., Berger, M. F., & Ladanyi, M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.005 · Cited by 148
Self-citationMalmgren, J. A., Mayer, M., Atwood, M. K., & Kaplan, H. G. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4529-5 · Cited by 159
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Patel, A., Unni, N. G., & Peng, Y. S. (2020) · Cancers · doi:10.3390/cancers12082081 · Cited by 165
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Friedlaender, A., Pérol, M., Banna, G. L., Parikh, K., & Addeo, A. (2024) · Biomarker Research · doi:10.1186/s40364-024-00566-0 · Cited by 178
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
Ponde, N. F., Brandão, M., El-Hachem, G., Werbrouck, E., & Piccart, M. J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.016 · Cited by 153
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
Indini, A., Rijavec, E., & Grossi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094774 · Cited by 153
Lee, C., Chon, H. J., Cheon, J., Lee, M. A., Im, H.-S., Jang, J.-S., Kim, M. H., Park, S., Kang, B., Hong, M., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00335-1 · Cited by 145
Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies
Picard, M., & Galvão, V. R. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.12.001 · Cited by 146
Gooding, A. J., & Schiemann, W. P. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0067 · Cited by 152
Resistance and Overcoming Resistance in Breast Cancer
Luque-Bolivar, A., Pérez-Mora, E., Villegas, V. E., & Rondón‐Lagos, M. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s270799 · Cited by 163
The Evolving Landscape of HER2 Targeting in Breast Cancer
Moasser, M. M., & Krop, I. E. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2286 · Cited by 137
Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies
Wang, Y., Ye, F., Liang, Y., & Yang, Q. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01424-8 · Cited by 150
Raghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00226 · Cited by 132
Savas, P. S., Teo, Z. L., Lefèvre, C. M., Flensburg, C., Caramia, F., Alsop, K., Mansour, M., Francis, P. A., Thorne, H., Silva, M. J., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002204 · Cited by 140
HER2-positive breast cancer: Current and new therapeutic strategies
Escrivá-de-Romaní, S., Arumí, M., Bellet, M., & Saura, C. (2018) · The Breast · doi:10.1016/j.breast.2018.03.006 · Cited by 152
Upton, R., Banuelos, A., Feng, D., Biswas, T., Kao, K., McKenna, K., Willingham, S., Ho, P. Y., Rosental, B., Tal, M. C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026849118 · Cited by 129
Marra, A., Chandarlapaty, S., & Modi, S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00849-9 · Cited by 157
Schettini, F., Buono, G., Cardalesi, C., Desideri, I., Placido, S. D., & Mastro, L. D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.03.012 · Cited by 144
Precision medicine: the foundation of future cancer therapeutics
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0016-z · Cited by 128
The La-Related Proteins, a Family with Connections to Cancer
Stavraka, C., & Blagden, S. P. (2015) · Biomolecules · doi:10.3390/biom5042701 · Cited by 147
Schmidt, K. T., Chau, C. H., Price, D. K., & Figg, W. D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.765 · Cited by 126
HER2-positive advanced breast cancer treatment in 2020
Cesca, M. G., Vian, L., Cristóvão‐Ferreira, S., Ponde, N. F., & de Azambuja, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102033 · Cited by 135
Sousa‐Pimenta, M., Estevinho, L. M., Szopa, A., Basit, M., Khan, K., Armaghan, M., Ibrayeva, M., Gürer, E. S., Călina, D. C., Hano, C., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1157306 · Cited by 134
Bone metastasis risk factors in breast cancer
Pulido, C., Vendrell, I., Ferreira, A. R., Casimiro, S., Mansinho, A., Alho, I., & Costa, L. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.715 · Cited by 134
Hwang, H. W., Jung, H., Hyeon, J., Park, Y. H., Ahn, J. S., Im, Y., Nam, S. J., Kim, S. W., Lee, J. E., Yu, J., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4981-x · Cited by 125
Self-citationThe Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors
Mijatović, S., Savic-Radojevic, A. R., Pljesa-Ercegovac, M. S., Simic, T. P., Nicoletti, F., & Maksimović‐Ivanić, D. (2020) · Antioxidants · doi:10.3390/antiox9050374 · Cited by 138
Bianchini, G., Kiermaier, A. C., Bianchi, G., Im, Y., Pieńkowski, T., Liu, M.-C., Tseng, L., Dowsett, M., Zabaglo, L. A., Kirk, S., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0806-9 · Cited by 131
Bone metastasis pattern in initial metastatic breast cancer: a population-based study
Xiong, Z., Deng, G., Huang, X., Li, X., Xie, X., Wang, J., Shuang, Z., & Wang, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s155524 · Cited by 124
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond
García‐Alonso, S., Ocaña, A., & Pandiella, A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.010 · Cited by 140
Johnston, S. R. D., Hegg, R., Im, S., Park, I. H., Burdaeva, O. N., Kurteva, G. P., Press, M. F., Tjulandin, S., Iwata, H., Simon, S. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01894 · Cited by 123
Breast surgery for metastatic breast cancer
Tosello, G. T., Torloni, M. R., Mota, B. S., Neeman, T. M., & Riera, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011276.pub2 · Cited by 146
Pharmacologic management of cognitive impairment induced by cancer therapy
Karschnia, P., Parsons, M. W., & Dietrich, J. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30938-0 · Cited by 120
Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers
Yu, J., Fang, T., Yun, C., Liu, X., & Cai, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.847835 · Cited by 133
Urruticoechea, A., Rizwanullah, M., Im, S., Ruiz, A. C. S., Láng, I., Tomasello, G., Douthwaite, H., Črnjević, T. B., Heeson, S., Eng‐Wong, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.6267 · Cited by 120
Self-citationCejalvo, J. M., Pascual, T., Fernández-Martínez, A., Brasó‐Maristany, F., Gomis, R. R., Perou, C. M., Muñoz-Mateu, M., & Prat, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.015 · Cited by 123
Voigtlaender, M., Schneider‐Merck, T., & Trepel, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_2 · Cited by 138
Master protocol trials in oncology: Review and new trial designs
Hirakawa, A., Asano, J., Sato, H., & Teramukai, S. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.009 · Cited by 132
Griguolo, G., Pascual, T., Dieci, M. V., Guarneri, V., & Prat, A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0548-6 · Cited by 127
Wagner, D., Grabsch, H. I., Mauer, M. E. L., Marreaud, S. I., Caballero, C. A., Thuss-Patience, P. C., Mueller, L., Elme, A., Moehler, M. H., Martens, U. M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5675-4 · Cited by 126
Arciero, C. A., Guo, Y., Jiang, R., Behera, M., O'Regan, R. M., Peng, L., & Li, X. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.02.001 · Cited by 132
Durkee, B. Y., Qian, Y., Pollom, E. L., King, M. T., Dudley, S. A., Shaffer, J. L., Chang, D. T., Gibbs, I. C., Goldhaber‐Fiebert, J. D., & Horst, K. C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9105 · Cited by 119
Bachelot, T., Ciruelos, E., Schneeweiß, A., Puglisi, F., Peretz‐Yablonski, T., Bondarenko, I., Paluch–Shimon, S., Wardley, A. M., Merot, J.-L., Toit, Y. D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz061 · Cited by 116
Self-citationThe Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
Patel, P. H., Palma, D. A., McDonald, F., & Tree, A. C. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.05.015 · Cited by 119
Schmitt, N. C., Kang, H., & Sharma, A. P. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.09.008 · Cited by 114
The RTK Interactome: Overview and Perspective on RTK Heterointeractions
Paul, M. D., & Hristova, K. A. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00467 · Cited by 127
Transcriptomics and solid tumors: The next frontier in precision cancer medicine
Tsimberidou, A. M., Fountzilas, E., Bleris, L. G., & Kurzrock, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.007 · Cited by 130
Ciruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 119
Self-citationBispecific antibodies in cancer therapy: Target selection and regulatory requirements
Sun, Y., Yu, X., Wang, X., Yuan, K., Wang, G., Hu, L., Zhang, G., Pei, W., Wang, L., Sun, C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.023 · Cited by 125
Breast cancer animal models and applications
Zeng, L., 昆明650223,中国, 中., Li, W., Chen, C., 昆明650204,中国, 中., & 中国科学院昆明动物研究所,KIZ-CUHK常见疾病生物资源与分子生物学联合研究室,云南昆明650223,中国 (2020) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.095 · Cited by 131
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“Breast cancer Pertuzumab + trastuzumab + docetaxel [113]; Paclitaxel + trastuzumab [114]”
BackgroundPerez, E. A., Barrios, C. H., EIERMANN, W., Toi, M., Im, Y., Conte, P., Martín, M., Pieńkowski, T., Pivot, X. B., Burris, H. A., et al. (2019) · Cancer · doi:10.1002/cncr.32392 · Cited by 122
Twenty years of anti-HER2 therapy-associated cardiotoxicity
Ponde, N. F., Lambertini, M., & de Azambuja, E. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000073 · Cited by 123
Diretriz Brasileira de Cardio-oncologia – 2020
Hajjar, L. A., Costa, I. B. S. D. S., Lopes, M. A. C. Q., Hoff, P. M., Estevez-Diz, M. D. P., Fonseca, S. M. R., Bittar, C. S., dos Santos, M. H. H., Rizk, S. I., Almeida, D. R., et al. (2020) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201006 · Cited by 156
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
García‐Álvarez, A., Papakonstantinou, A., & Oliveira, M. (2021) · Cancers · doi:10.3390/cancers13122927 · Cited by 118
Li, Y., Abudureheiyimu, N., Mo, H., Guan, X., Lin, S., Wang, Z., Chen, Y., Chen, S., Li, Q., Cai, R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.774577 · Cited by 110
Solinas, C., Ceppi, M., Lambertini, M., Scartozzi, M., Buisseret, L., Garaud, S., Fumagalli, D., de Azambuja, E., Salgado, R., Sotiriou, C. P., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.005 · Cited by 111
Ligorio, F., Fucà, G., Zattarin, E., Lobefaro, R., Zambelli, L., Leporati, R., Rea, C. G., Mariani, G., Bianchi, G., Capri, G., et al. (2021) · Cancers · doi:10.3390/cancers13081964 · Cited by 117
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Smyth, L. M., Piha-Paul, S. A., Won, H. H., Schram, A. M., Saura, C., Loi, S., Lu, J. M., Shapiro, G. I., Juric, D., Mayer, I. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0966 · Cited by 118
Self-citationTargeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review
Zhao, J., & Xia, Y. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00333 · Cited by 112
Jin, H., Du, W., Huang, W., Yan, J., Tang, Q., Chen, Y., & Zou, Z. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.08.005 · Cited by 122
Kim, Y., Js, K., & Kim, I. A. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2697-2 · Cited by 110
O'Sullivan, C. C., Bradbury, I., Campbell, C., Spielmann, M., Perez, E. A., Joensuu, H., Costantino, J. P., Delaloge, S., Rastogi, P., Zardavas, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8620 · Cited by 108
Pegram, M. D., Hamilton, E. P., Tan, A. R., Storniolo, A. M., Balic, K., Rosenbaum, A. I., Liang, M., He, P., Marshall, S., Scheuber, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0014 · Cited by 102
The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Bahrami, A., Khazaei, M., Shahidsales, S., Hassanian, S. M., Hasanzadeh, M., Maftouh, M., Ferns, G. A., & Avan, A. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26136 · Cited by 106
Babiker, H. M., McBride, A., Newton, M., Boehmer, L., Drucker, A., Gowan, M., Cassagnol, M., Camenisch, T. D., Anwer, F., & Hollands, J. M. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.014 · Cited by 111
Trastuzumab deruxtecan in breast cancer
Martín, M., Pandiella, A., Vargas-Castrillón, E., Díaz-Rodríguez, E., Iglesias-Hernangómez, T., Martínez Cano, C., Fernández-Cuesta, I., Winkow, E., & Perelló, M. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104355 · Cited by 103
Hurvitz, S. A., O’Shaughnessy, J., Mason, G., Yardley, D. A., Jahanzeb, M., Brufsky, A., Rugo, H. S., Swain, S. M., Kaufman, P. A., Tripathy, D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2366 · Cited by 109
Self-citationFayette, J., Wirth, L. J., Oprean, C. M., Udrea, A. A., Jimeno, A., Rischin, D., Nutting, C. M., Harari, P. M., Csőszi, T., Cernea, D. M., et al. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00232 · Cited by 107
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.